160 related articles for article (PubMed ID: 38614299)
1. The drug-specific properties of hypoxia-inducible factor-prolyl hydroxylase inhibitors in mice reveal a significant contribution of the kidney compared to the liver to erythropoietin induction.
Nakai T; Saigusa D; Kato K; Fukuuchi T; Koshiba S; Yamamoto M; Suzuki N
Life Sci; 2024 Jun; 346():122641. PubMed ID: 38614299
[TBL] [Abstract][Full Text] [Related]
2. Drugs activating hypoxia-inducible factors correct erythropoiesis and hepcidin levels via renal EPO induction in mice.
Nakai T; Iwamura Y; Kato K; Hirano I; Matsumoto Y; Tomioka Y; Yamamoto M; Suzuki N
Blood Adv; 2023 Aug; 7(15):3793-3805. PubMed ID: 37146271
[TBL] [Abstract][Full Text] [Related]
3. First-in-man-proof of concept study with molidustat: a novel selective oral HIF-prolyl hydroxylase inhibitor for the treatment of renal anaemia.
Böttcher M; Lentini S; Arens ER; Kaiser A; van der Mey D; Thuss U; Kubitza D; Wensing G
Br J Clin Pharmacol; 2018 Jul; 84(7):1557-1565. PubMed ID: 29575006
[TBL] [Abstract][Full Text] [Related]
4. Nonclinical Characterization of the Hypoxia-Inducible Factor Prolyl Hydroxylase Inhibitor Roxadustat, a Novel Treatment of Anemia of Chronic Kidney Disease.
Del Balzo U; Signore PE; Walkinshaw G; Seeley TW; Brenner MC; Wang Q; Guo G; Arend MP; Flippin LA; Chow FA; Gervasi DC; Kjaergaard CH; Langsetmo I; Guenzler V; Liu DY; Klaus SJ; Lin A; Neff TB
J Pharmacol Exp Ther; 2020 Aug; 374(2):342-353. PubMed ID: 32487538
[TBL] [Abstract][Full Text] [Related]
5. Preclinical Characterization of Vadadustat (AKB-6548), an Oral Small Molecule Hypoxia-Inducible Factor Prolyl-4-Hydroxylase Inhibitor, for the Potential Treatment of Renal Anemia.
Zuk A; Si Z; Loi S; Bommegowda S; Hoivik D; Danthi S; Molnar G; Csizmadia V; Rabinowitz M
J Pharmacol Exp Ther; 2022 Oct; 383(1):11-24. PubMed ID: 35926869
[TBL] [Abstract][Full Text] [Related]
6. JTZ-951 (enarodustat), a hypoxia-inducibe factor prolyl hydroxylase inhibitor, stabilizes HIF-α protein and induces erythropoiesis without effects on the function of vascular endothelial growth factor.
Fukui K; Shinozaki Y; Kobayashi H; Deai K; Yoshiuchi H; Matsui T; Matsuo A; Matsushita M; Tanaka T; Nangaku M
Eur J Pharmacol; 2019 Sep; 859():172532. PubMed ID: 31301309
[TBL] [Abstract][Full Text] [Related]
7. Hypoxia-Inducible Factor Prolyl Hydroxylase Inhibitors: A Potential New Treatment for Anemia in Patients With CKD.
Gupta N; Wish JB
Am J Kidney Dis; 2017 Jun; 69(6):815-826. PubMed ID: 28242135
[TBL] [Abstract][Full Text] [Related]
8. Mimicking hypoxia to treat anemia: HIF-stabilizer BAY 85-3934 (Molidustat) stimulates erythropoietin production without hypertensive effects.
Flamme I; Oehme F; Ellinghaus P; Jeske M; Keldenich J; Thuss U
PLoS One; 2014; 9(11):e111838. PubMed ID: 25392999
[TBL] [Abstract][Full Text] [Related]
9. Discovery of Molidustat (BAY 85-3934): A Small-Molecule Oral HIF-Prolyl Hydroxylase (HIF-PH) Inhibitor for the Treatment of Renal Anemia.
Beck H; Jeske M; Thede K; Stoll F; Flamme I; Akbaba M; Ergüden JK; Karig G; Keldenich J; Oehme F; Militzer HC; Hartung IV; Thuss U
ChemMedChem; 2018 May; 13(10):988-1003. PubMed ID: 29485740
[TBL] [Abstract][Full Text] [Related]
10. Hypoxia-inducible factor prolyl hydroxylase inhibitors: a paradigm shift for treatment of anemia in chronic kidney disease?
Souza E; Cho KH; Harris ST; Flindt NR; Watt RK; Pai AB
Expert Opin Investig Drugs; 2020 Aug; 29(8):831-844. PubMed ID: 32476498
[TBL] [Abstract][Full Text] [Related]
11. Erythropoietin and a hypoxia-inducible factor prolyl hydroxylase inhibitor (HIF-PHDi) lowers FGF23 in a model of chronic kidney disease (CKD).
Noonan ML; Clinkenbeard EL; Ni P; Swallow EA; Tippen SP; Agoro R; Allen MR; White KE
Physiol Rep; 2020 Jun; 8(11):e14434. PubMed ID: 32476270
[TBL] [Abstract][Full Text] [Related]
12. Hypoxia-inducible factor prolyl hydroxylase inhibitor in the treatment of anemia in chronic kidney disease.
Kurata Y; Tanaka T; Nangaku M
Curr Opin Nephrol Hypertens; 2020 Jul; 29(4):414-422. PubMed ID: 32452915
[TBL] [Abstract][Full Text] [Related]
13. Effects of post-renal anemia treatment with the HIF-PHD inhibitor molidustat on adenine-induced renal anemia and kidney disease in mice.
Li L; Nakano D; Zhang A; Kittikulsuth W; Morisawa N; Ohsaki H; Suzuki N; Yamamoto M; Nishiyama A
J Pharmacol Sci; 2020 Dec; 144(4):229-236. PubMed ID: 33070842
[TBL] [Abstract][Full Text] [Related]
14. TP0463518, a Novel Prolyl Hydroxylase Inhibitor, Specifically Induces Erythropoietin Production in the Liver.
Kato S; Ochiai N; Takano H; Io F; Takayama N; Koretsune H; Kunioka EI; Uchida S; Yamamoto K
J Pharmacol Exp Ther; 2019 Dec; 371(3):675-683. PubMed ID: 31585986
[TBL] [Abstract][Full Text] [Related]
15. Hypoxia-Inducible Factor Prolyl Hydroxylase Inhibitors and Iron Metabolism.
Ogawa C; Tsuchiya K; Maeda K
Int J Mol Sci; 2023 Feb; 24(3):. PubMed ID: 36769359
[TBL] [Abstract][Full Text] [Related]
16. A Novel Hypoxia-Inducible Factor-Prolyl Hydroxylase Inhibitor (GSK1278863) for Anemia in CKD: A 28-Day, Phase 2A Randomized Trial.
Brigandi RA; Johnson B; Oei C; Westerman M; Olbina G; de Zoysa J; Roger SD; Sahay M; Cross N; McMahon L; Guptha V; Smolyarchuk EA; Singh N; Russ SF; Kumar S;
Am J Kidney Dis; 2016 Jun; 67(6):861-71. PubMed ID: 26827289
[TBL] [Abstract][Full Text] [Related]
17. Effects of oral iron and calcium supplement on the pharmacokinetics and pharmacodynamics of molidustat: an oral HIF-PH inhibitor for the treatment of renal anaemia.
Lentini S; Kaiser A; Kapsa S; Matsuno K; van der Mey D
Eur J Clin Pharmacol; 2020 Feb; 76(2):185-197. PubMed ID: 31919558
[TBL] [Abstract][Full Text] [Related]
18. FGF23 expression in rodents is directly induced via erythropoietin after inhibition of hypoxia inducible factor proline hydroxylase.
Flamme I; Ellinghaus P; Urrego D; Krüger T
PLoS One; 2017; 12(10):e0186979. PubMed ID: 29073196
[TBL] [Abstract][Full Text] [Related]
19. Retinoic acid regulates erythropoietin production cooperatively with hypoxia-inducible factors in human iPSC-derived erythropoietin-producing cells.
Katagiri N; Hitomi H; Mae SI; Kotaka M; Lei L; Yamamoto T; Nishiyama A; Osafune K
Sci Rep; 2021 Feb; 11(1):3936. PubMed ID: 33594180
[TBL] [Abstract][Full Text] [Related]
20. Use of molidustat, a hypoxia-inducible factor prolyl hydroxylase inhibitor, in chronic kidney disease-associated anemia in cats.
Charles S; Süssenberger R; Settje T; Langston C; Lainesse C
J Vet Intern Med; 2024; 38(1):197-204. PubMed ID: 37740521
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
